| Summary | • A method to establish and maintain a reproducible, scalable valid reference standard for abnormalities on imaging, with special reference to findings not subject to biopsy, and for serial comparisons of therapy effects.  
• Classify bone scan results in selected representative reference populations from relevant cancer populations according to clinical groups of interest.  
• Evaluate the likelihood of cancer at each abnormal site by follow up, biopsy, or other diagnostic information normally available in the course of care.  
• Generate a reference panel and classify abnormal results for an individual patient. |
| Features and Benefits | • Value is derived from identifying the abnormal benign sites with low probability of metastasis versus abnormalities with high probability of metastasis, without resorting to biopsy.  
• This methodology makes it practical to conduct trials and care for patients with various bone scan findings without requiring biopsy date in many lesions, thereby greatly expanding the eligible patient populations for therapy trials and reduce overall costs.  
• This procedure establishes and maintains a reproducible, scalable valid reference standard for abnormalities on imaging, with special reference to findings not subject to biopsy, and for serial comparisons of therapy effects, based on probability estimates for metastasis. |
| Stage of Development | Initial concept stage and early database creation. |
| Inventor | Dr. E. Eikman |
| Publication and Patent Status | Manuscript submitted for publication. |
| Contact Information: | Haskell Adler PhD MBA  
Senior Licensing Manager  
Email: haskell.adler@moffitt.org  
Telephone: 813-745-6596  
H. Lee Moffitt Cancer Center and Research Institute, Inc.  
Office of Technology Management and Commercialization  
12902 Magnolia Drive MRC-TTO  
Tampa, FL 33612  
Website: http://www.moffitt.org/OTMC |